» Articles » PMID: 27014073

Cerebral Small Vessel Disease: Targeting Oxidative Stress As a Novel Therapeutic Strategy?

Overview
Journal Front Pharmacol
Date 2016 Mar 26
PMID 27014073
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Cerebral small vessel disease (SVD) is a major contributor to stroke, and a leading cause of cognitive impairment and dementia. Despite the devastating effects of cerebral SVD, the pathogenesis of cerebral SVD is still not completely understood. Moreover, there are no specific pharmacological strategies for its prevention or treatment. Cerebral SVD is characterized by marked functional and structural abnormalities of the cerebral microcirculation. The clinical manifestations of these pathological changes include lacunar infarcts, white matter hyperintensities, and cerebral microbleeds. The main purpose of this review is to discuss evidence implicating oxidative stress in the arteriopathy of both non-amyloid and amyloid (cerebral amyloid angiopathy) forms of cerebral SVD and its most important risk factors (hypertension and aging), as well as its contribution to cerebral SVD-related brain injury and cognitive impairment. We also highlight current evidence of the involvement of the NADPH oxidases in the development of oxidative stress, enzymes that are a major source of reactive oxygen species in the cerebral vasculature. Lastly, we discuss potential pharmacological strategies for oxidative stress in cerebral SVD, including some of the historical and emerging NADPH oxidase inhibitors.

Citing Articles

A bibliometric analysis of cerebral small vessel disease.

Yan X, Zhang Y, He R, Chen X, Lin M Front Aging Neurosci. 2024; 16:1400844.

PMID: 39435188 PMC: 11492496. DOI: 10.3389/fnagi.2024.1400844.


Role of NADPH Oxidases in Stroke Recovery.

Choi D, Choi I, Lee J Antioxidants (Basel). 2024; 13(9).

PMID: 39334724 PMC: 11428334. DOI: 10.3390/antiox13091065.


Blood urea nitrogen to albumin ratio is associated with cerebral small vessel diseases.

Nam K, Kwon H, Jeong H, Park J, Min K Sci Rep. 2024; 14(1):4455.

PMID: 38396162 PMC: 10891149. DOI: 10.1038/s41598-024-54919-8.


Diagnostic Performance Using a Combination of MRI Findings for Evaluating Cognitive Decline.

Byun J, Lee M, Jung S J Korean Soc Radiol. 2024; 85(1):184-196.

PMID: 38362402 PMC: 10864162. DOI: 10.3348/jksr.2023.0065.


Cerebral white matter burden is linked to cognitive function in patients undergoing hemodialysis.

Wu T, Wu P, Lin H, Chen W, Huang T, Lin M Ann Med. 2024; 56(1):2310142.

PMID: 38324920 PMC: 10851831. DOI: 10.1080/07853890.2024.2310142.


References
1.
Faraco G, Moraga A, Moore J, Anrather J, Pickel V, Iadecola C . Circulating endothelin-1 alters critical mechanisms regulating cerebral microcirculation. Hypertension. 2013; 62(4):759-66. PMC: 3874144. DOI: 10.1161/HYPERTENSIONAHA.113.01761. View

2.
Csanyi G, Cifuentes-Pagano E, Al Ghouleh I, Ranayhossaini D, Egana L, Lopes L . Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2. Free Radic Biol Med. 2011; 51(6):1116-25. PMC: 3204933. DOI: 10.1016/j.freeradbiomed.2011.04.025. View

3.
Iadecola C, Zhang F, Niwa K, Eckman C, Turner S, FISCHER E . SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci. 1999; 2(2):157-61. DOI: 10.1038/5715. View

4.
Choi D, Kim J, Lee K, Kim H, Kim Y, Choi W . Role of neuronal NADPH oxidase 1 in the peri-infarct regions after stroke. PLoS One. 2015; 10(1):e0116814. PMC: 4305324. DOI: 10.1371/journal.pone.0116814. View

5.
Ebinger M, Brunecker P, Schultze-Amberger J, Gertz K, Muller B, Fiebach J . Statins and cerebral perfusion in patients with leukoaraiosis--a translational proof-of-principal MRI study. Int J Stroke. 2012; 7(7):E5. DOI: 10.1111/j.1747-4949.2012.00807.x. View